IDM Pharma gets new CEO as founder departs

IDM Pharma said founder, president and CEO Jean-Loup Romet-Lemonne is leaving to "pursue other opportunities." The board named Timothy Walbert, the former EVP of commercial operations at NeoPharm, to the CEO's job.

"Our immediate priority will be continuing to work with the regulatory authorities in the U.S. and Europe to complete the review process of Junovan," says Walbert. "Based on the Phase III results of the trial with Junovan, we are committed to an ongoing dialogue with the FDA and EMEA and believe that Junovan has the potential to be an important treatment for children with osteosarcoma."

- here's the release on the executive shuffle

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.